ID 289 -
Krzem
PL: Krzem
EN: Silicon
Pdf: silicon
1. Charakterystyka żywności / składnika
The food constituents that are the subjects of the health claims are “silicon”, “silicon (as stabilised oligomeric orthosilicic acid (OSA))”, “choline-stabilised orthosilicic acid (ch-OSA)”, “Mineral- wasser/Kieselsäure (Silizium)”, “silica/silicious earth”, and “monométhylsilanetriol”.
From the references and conditions of use provided in relation to the health claims considered in this opinion, the Panel assumes that the food constituent under evaluation is silicon.
Silicon is authorised for addition to foods (Annex I of Regulation (EC) No 1925/20066 and Annex I of Directive 2002/46/EC7). This evaluation applies to silicon naturally present in foods and added to foods.
Silicon occurs naturally in foods as silicon dioxide (silica, SiO2) and silicates, and may also be added to foods as an anti-caking and anti-foaming agent in the form of silica, silicates and dimethylpolysiloxane. Silicate-containing antacids have been widely used for a number of decades.
Orthosilicic acid [Si(OH)4] or mono-silicic acid is a water soluble form of silicon. A saturated solution contains 0.1 % silicic acid. Silicic acid can also exist as an oligomer and as polysilicic acid (EFSA, 2004). Oligomeric silica (oligomeric orthosilicic acid) is formed as a meta-stable intermediate in the progressive polymerisation of silicic acid in saturated solutions. Monomethylsilanetriol, also called organic silicon (CH3-Si-(OH)3), and choline-stabilised orthosilicic acid (ch-OSA) are usually added to food supplements as a source of silicon (EFSA, 2009a, 2009b).
The Panel considers that the food constituent, silicon, which is the subject of the health claims, is sufficiently characterised.
2.2. Zdrowie serca i naczyń (ID 289)
The claimed effect is “cardiovascular health”. The Panel assumes that the target population is the general population.
The claimed effect is not sufficiently defined and no further details were provided in the proposed wordings. No further clarifications were provided by Member States.
The Panel considers that the claimed effect is general and non-specific, and does not refer to any specific health claim as required by Regulation (EC) No 1924/2006.
Warunki i możliwe ograniczenia stosowania oświadczenia
5-10 mg of OSA
Must meet minimum requirements for use of the claim "source of [name of vitamin/s] and/or [name of mineral/s]" as per Annex to Regulation 1924/2006.